Document Detail


Therapy for chronic hepatitis C.
MedLine Citation:
PMID:  11595466     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: in Hungary, over the past 5 years more than 900 patients with chronic hepatitis C have been examined for treatment with interferon at 16 major hepatology centres, using unified diagnostic and therapeutical criteria. Authors give an account of their experiences on the clinical features of patients with chronic hepatitis C and report the results of the interferon therapy. METHODS: a total of 993 patients--virtually the entire Hungarian hepatitis C patient population who had been referred for interferon treatment--were included in the program. Actually, the sustained efficacy of the therapy was evaluated in 724 cases. Treatment protocols (dose of interferon and duration of therapy) have changed with time from a weekly dose of 3x3 MU IFN for 6 months in the first period, to 3x3-5 MU for 12 months in the second period, and finally in the third period a combination therapy with ribavirin has also been introduced. RESULTS: in the first period, the end-of-treatment response (ETR) was 35%, sustained response (SR) 13%, the second phase schedule resulted in 42% ETR and 22% SR, while in the third period, ETR was 49% and SR 36%, respectively. Fibrosis in histology and baseline pretreatment HCV-RNA level appeared as predictors of response. The duration of treatment and the total dose of interferon exerted a moderate effect on therapeutic efficacy. Neither age nor gender influenced the outcome. CONCLUSIONS: our results-obtained in a Central East European country-are in accordance with findings of suboptimal efficacy of traditional interferon monotherapy for chronic hepatitis C reported in the West, and suggest the benefit of the combination treatment of interferon with ribavirin.
Authors:
A Pár; L Telegdy; L Dalmi; E Müller;
Related Documents :
19586556 - Efficacy of consensus interferon in treatment of hbeag-positive chronic hepatitis b: a ...
14642626 - When and how to treat acute hepatitis c?
12102166 - Impact of highly active antiretroviral therapy in the treatment of hiv-infected patient...
3187296 - Adverse reactions in long-term interferon treatment.
8312766 - Collaborative overview of randomised trials of antiplatelet therapy--ii: maintenance of...
17234456 - World apheresis registry report.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of physiology, Paris     Volume:  95     ISSN:  0928-4257     ISO Abbreviation:  J. Physiol. Paris     Publication Date:    2001 Jan-Dec
Date Detail:
Created Date:  2001-10-11     Completed Date:  2002-02-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9309351     Medline TA:  J Physiol Paris     Country:  France    
Other Details:
Languages:  eng     Pagination:  399-405     Citation Subset:  IM    
Affiliation:
First Department of Medicine, Faculty of Medicine, University of Pécs, Ifjuság u.13, H-7643, Pécs, Hungary
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antiviral Agents / administration & dosage,  therapeutic use*
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Hepacivirus / genetics
Hepatitis C, Chronic / blood,  drug therapy*,  pathology,  virology
Humans
Interferons / administration & dosage,  therapeutic use*
Liver / pathology
Male
Middle Aged
Prognosis
RNA, Viral / blood
Ribavirin / therapeutic use
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/RNA, Viral; 36791-04-5/Ribavirin; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Different affinity states of CCK(1) receptors on pancreatic acini and gastric smooth muscle in the r...
Next Document:  Treatment of primary biliary cirrhosis.